Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights KN026 (Anbenitamab) achieved robust...
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
SUZHOU, China, March 20, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug...
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The event focused on...
Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- The 16th World ADC San Diego, held from November 3–6, 2025, brought together industry leaders in San Diego, USA. Dr. Ting Xu, Founder, Chairman, and CEO of Alphamab Oncology, was invited to deliver a...